All In Biotech

Drug Trial Radar · NCT02671175

Post-discharge Malaria Chemoprevention(PMC) Study

Malaria Chemoprevention With Monthly Treatment With Dihydroartemisinin-piperaquine for the Post-discharge Management of Severe Anaemia in Children Aged Less Than 5 Years in Uganda and Kenya: A Two-arm Randomised Placebo Controlled Trial

Last checked: Nov 20, 2026Latest source record: Jun 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,049 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,049

Actual

Start

May 20, 2016

Primary completion

Oct 24, 2018

Study completion Dec 12, 2018

Sponsor

Lead sponsor
Liverpool School of Tropical MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Research Council of Norway; Kenya Medical Research Institute; Makerere University
First posted
Feb 2, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, up to 60 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the efficacy and safety of 3 months of malaria chemoprevention post-discharge using dihydroartemisinin piperaquine (DHA-P) in children under 5 years of age admitted with severe anemia. One half will receive monthly DHA-P and the other half placebo.

Conditions

  • Malaria
  • Severe Anemia

Interventions

  • dihydroartemisinin-piperaquineDrug

    Children in both arms will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.

  • dihydroartemisinin-piperaquine placeboDrug

    Children will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause deaths or all-cause re-admissions by 26 weeks from randomization (composite primary outcome).Time frame: 6 months

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Jaramogi Oginga Odinga Teaching and Referral Hospital

    Kisumu, Kenya

  • Homa Bay County Referral Hospital

    Homa Bay, Homa Bay County, Kenya

  • Migori County Referral Hospital

    Migori, Migori County, Kenya

  • Siaya County Referral Hospital

    Siaya, Siaya County, Kenya

  • Hoima Regional Referral Hospital

    Hoima, Uganda

  • Jinja Regional Referral Hospital

    Jinja, Uganda

  • Kamuli Mission Hospital

    Kamuli, Uganda

  • Masaka Regional Referral Hospital

    Masaka, Uganda

  • Mubende Regional Referral Hospital:

    Mubende, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.